
Pharmaceuticals · NSE / BSE
Supriya Lifescience is a manufacturer of Active Pharmaceutical Ingredients (APIs), producing 38 APIs across therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatics, and anti-allergics. Between FY 2017 and FY 2021, it was the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, and one of the largest exporters of Salbutamol Sulphate in FY 2021. The company exports to 86 countries, serving 1,296 customers, including 346 distributors, across Europe, Latin America, Asia, and North America. Its modern manufacturing facility in Maharashtra spans 23,806 sq. m with a reactor capacity of 547 KL/day and seven clean rooms. Supriya Lifescience has acquired an additional 12,551 sq. m plot for expansion and holds regulatory approvals from USFDA, EDQM, TGA-Australia, KFDA-Korea, PMDA-Japan, NMPA-China, and Health Canada for its API exports.
Price Band
₹265 – ₹274
Issue Size
₹700 Cr
Lot Size
54 shares
GMP
+47.5%
Est. Listing
₹404
at current GMP
Subscribed
—
Open
16 Dec 2021
Close
20 Dec 2021
Allotment
23 Dec 2021
Refund
24 Dec 2021
Demat Credit
25 Dec 2021
Listing
28 Dec 2021
Designated Registrar: Link Intime India Private Limited
Allotment Date
23 Dec 2021
Basis finalization
Refunds Initiate
24 Dec 2021
Mandate release
Demat Credit
25 Dec 2021
Shares in demat
Listing Debut
28 Dec 2021
Trading begins
Supriya Lifescience Limited is bringing an initial public offering (IPO) in the Pharmaceuticals sector with an aggregate issue size of ₹700 Crores. The shares are offered at a price band of ₹265 to ₹274 per equity share on NSE and BSE. Currently, grey market participants and retail investors are watching the bidding trend, premium movement, and anchor book demand with keen interest.
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 54 shares (approx. ₹14,796 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment reconciliation will be managed by Link Intime India Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2021-12-25, while un-allotted funds or UPI block mandates will be released on 2021-12-24.
Allotment records are updated in batches. If the status is not yet available, please wait a few hours until the basis of allotment is fully finalized.
Since funds are blocked under ASBA/UPI, the bank will automatically release the blocked hold on your funds upon receipt of revocation instructions from the sponsor bank.